局部晚期乳腺癌TE方案密集新辅助化疗临床观察  

Therapeutic efficacy of the neoadjuvant chemotherapy with dose-dense TE regimen in locally advanced breast cancer

作　　者：王建玲[1] 吕月涛[1] 

机构地区：[1]济宁市第一人民医院乳甲外科,山东济宁272100

出　　处：《中华肿瘤防治杂志》2014年第22期1816-1819,共4页Chinese Journal of Cancer Prevention and Treatment

摘　　要：目的观察多西他赛联合表柔比星（TE方案）密集新辅助化疗治疗局部晚期乳腺癌（locally advanced breast cancer,LABC）的疗效和毒副作用。方法收集济宁市第一人民医院乳甲外科2008-01-01-2012-12-31收治的39例未经治疗的LABC患者接受TE方案密集新辅助化疗。TE方案：多西他赛75 mg/m2,持续1h静脉滴入,d1;表柔比星75mg/m2,静脉滴入,d1。14d为1个周期,共2-4个周期。患者治疗前均经组织穿刺活检明确诊断。结果 TE方案密集新辅助化疗在LABC的治疗中总有效率为74.4%,其中完全缓解6例（15.4%）,部分缓解23例（59.0%）。患者3年无病生存率和总生存率分别为84.1%和96.7%。所有患者均有不同程度的白细胞下降及脱发,其次为恶心、呕吐、肝功能损害及腹泻,无化疗相关性死亡。结论 TE方案密集新辅助化疗在取得理想的治疗效果的同时缩短了治疗周期,有利于早日手术,且毒副作用可耐受。OBJECTIVE To investigate the therapeutic effect and side reaction of neoadjuvant chemotherapy with the dose-dense TE （T.. docetaxel, E.. epirubicin）regimen in locally advanced breast cancer（LABC）. METHODS Thirty- nine patients with LABC were treated with dose-dense TE regimen before operation. TE regimen（docetaxel 75 mg/m2 , dl; epirubicin, 75 mg/m2 , dl ） was administered every 2 weeks for 2-4 cycles before local treatment. Core needle biopsy was carried out before the initiation of chemotherapy. RESULTS The overall response rate was 74.4%, CR was found in 6 cases （15. 4%）, while PR in 23 cases （59.0%）. The three-year disease-free survival （DFS） rate was 84.1%, three- year over survival （OS）rate was 96.7 %. Leukopenia and alopecia was found in all the patients. The other side reactions were nausea, vomiting, liver damage and diarrhea. ,but there were no deaths caused by chemotherapy. CONCLUSION Dose-dense TE regimen as neoadjuvant chemotherapy can achieve therapeutic efficacy with decreased treatment duration and tolerable toxicity. EKEYWORDS] breast neoplasms ~ neoadjuvant chemotherapy~ docetaxel ~ epirubicin

关 键 词：乳腺肿瘤 新辅助化疗 多西他赛 表柔比星 

分 类 号：R737.9[医药卫生—肿瘤]